Pharmacokinetics and Pharmacodynamics of BI 10773 After Single and Multiple Oral Dose of 10 mg and 25 mg BI 10773 in Chinese Male and Female Type 2 Diabetic Patients.
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2016
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 16 Sep 2016 Results assessing safety data from 18 trials presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 08 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.